RWP
CRSP icon

RWA Wealth Partners’s CRISPR Therapeutics CRSP Stock Holding History

RWA Wealth Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,505
Closed -$227K – 608
2025
Q3 		$227K Buy
+3,505
New +$201K ﹤0.01% 577

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
GP
GSK plc London $602M AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RWA Wealth Partners's CRSP Position: Q4 2025 in Review

RWA Wealth Partners sold out of CRISPR Therapeutics (CRSP) in Q4 2025, closing a stake of 3,505 shares — an estimated $227K sold.

RWA Wealth Partners first reported a position in CRSP in Q3 2025 and held it in 1 quarter. The position peaked at $227K in Q3 2025. 480 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

  • RWA Wealth Partners reported no remaining CRISPR Therapeutics position as of Q4 2025 after selling out during the quarter.
  • RWA Wealth Partners sold 3,505 CRISPR Therapeutics shares in Q4 2025, an estimated $227K.
  • RWA Wealth Partners first reported a position in CRISPR Therapeutics in Q3 2025 and held it in 1 quarter.
  • RWA Wealth Partners's CRISPR Therapeutics position peaked at $227K in Q3 2025.
  • 480 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on RWA Wealth Partners's 13F filing for Q4 2025, filed 12 Feb 2026.